NEW YORK CITY, NY / ACCESS Newswire / March 16, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds ...

GSK said this month that it’s making progress in late-stage development of several oncology drugs, though vaccine sales are falling.

GSK's revenue and EPS exceeded my expectations and those of analysts, thanks to the strong performance of its oncology and HIV franchises. So, Ojjaara/Omjjara sales amounted to $150 million in the ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...

One of the most highly anticipated FDA decisions this month is for Alnylam Pharmaceuticals, which is seeking to expand the ...

having been knocked back by US lawsuits over the alleged cancer risks of discontinued heartburn drug Zantac. Even after GSK reached a $2.2bn settlement in October, resolving the majority of cases ...

Two recent high-profile acquisitions exemplify this trend; Eli Lilly’s pursuit of Scorpion Therapeutics and GSK’s acquisition of IDRx. Eli Lilly’s Bold Bid to Lead Oncology Eli Lilly’s ...

GSK reported core earnings of 59 cents per American ... Sales grew in double digits in HIV, Immunology/Respiratory as well as Oncology segments. HIV sales rose 14% driven by strong demand and ...